Shionogi just made its biggest rare disease play yet. The Japanese drugmaker is buying Anglo-US biotech IntraBio for $2 billion. This deal puts Shionogi on a new path. The company wants to move past its old anti-infective focus and become a real player in rare diseases.
Aqneursa (levacetylleucine) sits at the heart of the deal. It’s the first approved treatment for ataxia-telangiectasia (A-T), a severe inherited brain disorder. Aqneursa also got regulatory approval in 2024 for treating neurological symptoms in Niemann-Pick disease type C (NPC), another rare genetic illness. IntraBio already has European approval for Aqneursa in NPC. The company is still waiting for a decision on the A-T use.
Shionogi’s board approved the IntraBio acquisition on October 5, 2026, with the agreement signed the same day, setting the stage for IntraBio to become a wholly owned subsidiary.
Strategic expansion beyond anti-infectives
Shionogi has picked up speed in rare diseases over the last year. The company recently bought Tanabe Pharma’s Radicava (edaravone) line for ALS. That product brings in about $700 million a year worldwide. In 2023, Shionogi also spent $1 billion to buy Torii Pharma, the drug arm of Japan Tobacco. That deal boosted Shionogi’s reach in skin, kidney, and allergy drugs both in Japan and abroad.
IntraBio started in Oxford, UK, and now runs from Austin, Texas. Last year, it reported just under $70 million in net sales from its rare disease drugs. The company is private and keeps most sales numbers quiet. But Shionogi’s filings confirm IntraBio’s commercial reach. An official company statement says the $2 billion upfront price for all IntraBio shares shows how much Shionogi values rare disease innovation, even compared to current sales.
Pipeline and future commitments
If the deal closes between November and December as planned, Shionogi will take over a pipeline with clinical-stage drugs for Pompe disease, Fragile X syndrome, and Jordan’s syndrome. There are also early programs for other rare brain disorders. Shionogi says bringing in IntraBio will “deepen our commitment to rare disease communities, expand our capabilities, and strengthen our portfolio as we advance future innovation for patients with significant unmet needs.”
The transaction is expected to close between November and December 2026, subject to customary closing conditions, including regulatory approvals and competition-law clearances in relevant countries.
Chief executive Isao Teshirogi put it plainly. “The planned acquisition of IntraBio actively demonstrates Shionogi's solid commitment to building a leading global rare disease business.”
Shionogi’s approach matches a bigger trend. Big pharma companies are buying up smaller firms to branch out. Recent deals like the Zymeworks respiratory buyout show the same pattern. But Shionogi is zeroing in on rare brain and genetic diseases. These are tough markets with few rivals and high hurdles for approval and sales.
This isn’t just a product buy. Shionogi is grabbing a spot in a field where science is hard and patient needs are urgent. The company is willing to spend big. That’s a clear break from its anti-infective past. If Shionogi can turn its infectious disease know-how into rare disease results, it could become a major force. Few have managed to scale both science and business here.
Reuters market coverage says the deal aims to grow Shionogi’s rare-disease lineup and move the company beyond its old anti-infective focus. That matches Shionogi’s stated strategy.
